Zongertinib tablet study in healthy volunteers
This study tests how well the body absorbs a drug called zongertinib when it is given as tablets from two different manufacturers, with or without food. It helps researchers understand the best way to take the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- Your body mass index (BMI) must be between 18.5 and 29.9 kg/m².
- You must be in good health, as confirmed by a physical exam and routine lab tests.
- You must have normal blood pressure, pulse, and heart rhythm.
- You must be able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study in healthy volunteers looks at how much of the drug BI 3034701 enters the bloodstream when given in two different ways. It helps find the best way to deliver the drug for future studies.
This is an early-stage safety study testing a new experimental drug called ZE74-0282 in healthy volunteers. Researchers want to learn how safe the drug is and how well people tolerate it before testing it in patients with a disease.
This study tests a new medicine called ZL-1503 in healthy people to see how the body processes it and if it's safe. It helps doctors learn the right dose for future studies.
This study tests a new tablet in healthy adults to see how the body processes it and whether food changes its effects. It helps determine the right dose and safety for future patients.
This early-stage study tests how a new experimental medication (HSK55879) is tolerated and processed by the body in healthy volunteers. Researchers will also check how food affects the drug's absorption to help determine safe dosing for future patient studies.
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.